Poster Presentation ESA-SRB-ANZBMS 2024 in conjunction with ENSA

Prevalence of low-renin in the general population and relationship to blood pressure and cardiovascular disease (#560)

Sonali S Shah 1 2 3 , Stella M Gwini 2 4 , Kara L Holloway-Kew 5 , Julie A Pasco 4 5 , Lana Williams 5 , Jun Yang 1 2 3
  1. Endocrinology, Monash Health, Clayton, VIC, Australia
  2. Centre of Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, VIC , Australia
  3. Department of Molecular and Translational Science , Monash University, Clayton, Victoria, Australia
  4. School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
  5. IMPACT – the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University , Geelong, Victoria, Australia
Publish consent withheld
  1. Shah SS, Zhang J, Gwini SM, Young MJ, Fuller PJ, Yang J. Efficacy and safety of mineralocorticoid receptor antagonists for the treatment of low-renin hypertension: a systematic review and meta-analysis. J Hum Hypertens. 2024;38:383-392. doi: 10.1038/s41371-023-00891-1
  2. Brown JM, Robinson-Cohen C, Luque-Fernandez MA, Allison MA, Baudrand R, Ix JH, Kestenbaum B, de Boer IH, Vaidya A. The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study. Ann Intern Med. 2017;167:630-641. doi: 10.7326/M17-0882
  3. Hu J, Shen H, Huo P, Yang J, Fuller PJ, Wang K, Yang Y, Ma L, Cheng Q, Gong L, et al. Heightened Cardiovascular Risk in Hypertension Associated With Renin-Independent Aldosteronism Versus Renin-Dependent Aldosteronism: A Collaborative Study. J Am Heart Assoc. 2021;10:e023082. doi: 10.1161/JAHA.121.023082
  4. Pasco JA, Nicholson GC, Kotowicz MA. Cohort profile: Geelong Osteoporosis Study. Int J Epidemiol. 2012;41:1565-1575. doi: 10.1093/ije/dyr148